These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12678241)

  • 1. Adoption of three Rs alternatives for regulatory testing of vaccines in the developing world: possibilities and barriers.
    Di Fabio JL; Jaramillo MT; Arciniega JL
    Dev Biol (Basel); 2002; 111():195-8. PubMed ID: 12678241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of alternatives to animal tests in developing countries.
    Hong HA; Hendriks J
    Dev Biol Stand; 1999; 101():209-14. PubMed ID: 10566795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potency tests of diphtheria, tetanus and combined vaccines. Suggestion for a simplified potency assay.
    Aggerbeck H; Heron I
    Dev Biol Stand; 1996; 86():297-301. PubMed ID: 8785958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards eliminating the use of animals for regulatory required vaccine quality control.
    Hendriksen CF
    ALTEX; 2006; 23(3):187-90. PubMed ID: 17086348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WHO activities towards the three Rs in the development and control of biological products.
    Milstien J; Grachev V; Padilla A; Griffiths E
    Dev Biol Stand; 1996; 86():31-9. PubMed ID: 8785961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Vero cell method for potency testing of diphtheria vaccines.
    Winsnes R; Sesardic D; Daas A; Rigsby P
    Dev Biol (Basel); 2002; 111():141-8. PubMed ID: 12678233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an in vitro potency test for tetanus vaccines: an immunoassay based on Hc fragment determination.
    Prieur S; Broc S; Gal M; Poirier B; Fuchs F
    Dev Biol (Basel); 2002; 111():37-46. PubMed ID: 12678223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A short history of the use of animals in vaccine development and quality control.
    Hendriksen CF
    Dev Biol Stand; 1996; 86():3-10. PubMed ID: 8785959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement.
    Hendriksen CF
    Expert Rev Vaccines; 2009 Mar; 8(3):313-22. PubMed ID: 19249973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A consideration of some methods by which the cost of potency assays for diphtheria and tetanus vaccines might be reduced.
    Knight PA
    Dev Biol Stand; 1978; 41():67-72. PubMed ID: 753671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory processes and three Rs alternatives.
    Milstien J
    Dev Biol (Basel); 2002; 111():15-9. PubMed ID: 12678220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternatives to animals in the development and control of biological products for human and veterinary use. The role of the European Pharmacopoeia.
    Artiges A
    Dev Biol Stand; 1999; 101():29-35. PubMed ID: 10566772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consistency testing of diphtheria and tetanus to replace potency testing for lot release.
    Kreeftenberg JG
    Dev Biol (Basel); 2002; 111():291-8. PubMed ID: 12678252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and opportunities for the implementation of the Three Rs in Canadian vaccine quality control.
    Long ME; Griffin G
    Regul Toxicol Pharmacol; 2012 Aug; 63(3):418-25. PubMed ID: 22634245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The three Rs of Russell & Burch and the testing of biological products.
    Balls M; Straughan DW
    Dev Biol Stand; 1996; 86():11-8. PubMed ID: 8785939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternatives to animal experimentation: the regulatory background.
    Garthoff B
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):388-92. PubMed ID: 15982684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Batch potency testing of inactivated erysipelas vaccines by ELISA--development, validation and implementation.
    Rosskopf-Streicher U; Johannes S; Gyra H; Beckmann R; Cussler K
    Dev Biol (Basel); 2002; 111():153-8. PubMed ID: 12678235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency assays for therapeutic live whole cell cancer vaccines.
    Petricciani J; Egan W; Vicari G; Furesz J; Schild G
    Biologicals; 2007 Apr; 35(2):107-13. PubMed ID: 16882459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation and validation of a single-dilution potency assay based upon serology of vaccines containing diphtheria toxoid: analysis for consistency in production and testing.
    Akkermans AM; Hendriksen CF; Marsman FR; van de Donk HJ
    Dev Biol Stand; 1996; 86():323-4. PubMed ID: 8785964
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.